Navigation Links
Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
Date:9/1/2013

AMSTERDAM, The Netherlands and OSAKA, Japan, Sept. 2, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) today announced results of the EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) cardiovascular (CV) safety outcomes trial, showing the primary endpoint of non-inferiority compared to placebo in addition to standard of care was met with no increase in CV risk in a Type 2 diabetes patient population at high-risk for CV events. These data, published in the New England Journal of Medicine (NEJM) and also presented at the ESC Congress 2013, demonstrate that alogliptin does not increase CV risk in Type 2 diabetes patients at high-risk for major adverse cardiac events (MACE) due to a recent acute coronary syndrome (ACS). The trial's primary objective was to evaluate non-inferiority of CV risk based on a primary composite endpoint of CV death, nonfatal myocardial infarction and nonfatal stroke. The primary endpoint occurred at similar rates in the alogliptin and placebo groups (in 11.3% of patients vs. 11.8% of patients during a median follow-up period of 18 months; hazard ratio, 0.96; one-sided repeated confidence interval [CI] bound, 1.16). Alogliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4i) for the treatment of Type 2 diabetes in adults to improve glycemic control as an adjunct to diet and exercise.

"There is a need for safer glucose lowering therapies in patients with diabetes who are at an elevated risk for cardiovascular disease," stated William B. White, MD, FASH, FAHA, FACP, principal investigator of the EXAMINE trial. "Given the EXAMINE study design and high-risk patient population evaluated, these results provide key insights to clinicians treating diabetes patients with coronary disease."

The global EXAMINE trial is an im
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimers Disease in Subjects Selected Using a Genetic-Based Biomarker Risk Assignment Algorithm
2. Takeda Launches New Subsidiary in Peru
3. Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcerative Colitis and Crohns Disease
4. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
5. Takeda Submits Biologics License Application for a New Investigational Drug Vedolizumab, in Moderately to Severely Active Crohns Disease and Ulcerative Colitis in the United States
6. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
7. AGA Research Foundation Announces Endowment Gift from Takeda Pharmaceuticals U.S.A., Inc. to Support Gastroenterology Research
8. Takeda to Acquire Inviragen, Inc.
9. Takeda Responds to Verdict in Diabetes Drug Case
10. Takeda Launches New Subsidiary in Ecuador
11. Takeda lanza nueva subsidiaria en Ecuador
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Calif. , Nov. 26, 2014   Regulus ... biopharmaceutical company leading the discovery and development of innovative ... Xanthopoulos , Ph.D., President and CEO of Regulus, will ... Annual Piper Jaffray Healthcare Conference at the New York ... p.m. EST.  The presentation will be webcast at the ...
(Date:11/26/2014)... ® , Inc. (NASDAQ: BIOS ) announced today that ... present at the Bank of America Merrill Lynch 2014 Leveraged Finance ... , , Wednesday, December 3, 2014 , , , , ... , Location: , , , Boca Raton Resort and Club, Florida ... BioScrip, Inc. is a leading national provider of infusion ...
(Date:11/26/2014)... Nov. 26, 2014 The medical magnetic ... rate of 4%, with world market revenues for ... MRI and other types of medical imaging have ... of numerous medical conditions in children and adults, ... Kalorama,s report, Medical Imaging Markets , analyzes ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Written and narrated ... Brook Forest Voices releases the “The Happiest Man In ... a compelling account of how and why Project C.U.R.E. came ... by his mother Josie and the Reverend Richard W. Jackson, ... the age of 30, but realized that he wasn’t happy. ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., was using ... was almost impossible to reach. "This gave me the idea ... patent-pending Access Light allows for easier use of a dental ... as well as avoids harm to the lips, tongue and ... clean, it also helps prevent cross-contamination. , The original design ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... ( http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed in ... of recalled metal implants, Bernstein Liebhard LLP reports. ... 18th in Bergen County Superior Court reflects the ... ABG II modular-neck hip stems, which were voluntarily ...
Breaking Medicine News(10 mins):Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3
... earlier research which said that fish was capable of scaling ... are present in fish do not serve to reduce cancer ... has however been // witnessed in the case of people ... ,Several trials have attempted to assess the effects of ...
... health department officials have proposed the administration of flu vaccine ... in an attempt to prevent the incidence of seasonal flu. ... the population during winter, had claimed the valuable lives of ... Committee on Vaccination and Immunisation that addresses important medical issues ...
... Cancer Society is planning to start “Hope Lodges” near ... patients when they are getting treatment in these major ... free accommodation to these patients who are coming from ... lodges could provide staying facilities to these patients during ...
... Mexico Hospitals and Health Systems Association has launched a ... into the quality of treatment// offered by the hospital ... selecting the hospital for their treatment. ,There ... website provides information about the number of patients visiting ...
... Chengcheng Zhang from Whitehead Institute for Biomedical Research in Cambridge ... increases the number of stem cells in the laboratory before ... ,Stem cell therapy as shown that the quantity of stem ... requires isolating large number of stem cells. Stem cells for ...
... respective mothers, after they were swapped due to nursing error that ... women delivered surgical babies in the Ranchi Institute of Medical Science ... at 10.30 p.m. and Meena Devi gave birth to a son ... before I. When Savitri was shifted to my ward I heard ...
Cached Medicine News:
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... catheter positioning and exchange ... inner diameter of wire ... of an extra heavy ... tip flexibility. Supplied sterile ...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: